Context Therapeutics Inc. (CNTX)
- Previous Close
2.4500 - Open
2.4700 - Bid 2.4200 x 500
- Ask 2.4800 x 200
- Day's Range
2.4300 - 2.4900 - 52 Week Range
0.7700 - 2.7500 - Volume
26,995 - Avg. Volume
242,026 - Market Cap (intraday)
184.496M - Beta (5Y Monthly) 2.30
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.63
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
www.contexttherapeutics.comRecent News: CNTX
View MorePerformance Overview: CNTX
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTX
View MoreValuation Measures
Market Cap
184.50M
Enterprise Value
159.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.19%
Return on Equity (ttm)
-29.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.57M
Diluted EPS (ttm)
-0.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
101.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.33M